Results of our study showed no significant difference either in incidence or severity of cGvHD between both groups. These results were consistent with a study done by Mielcarek et al, on 44 patients who underwent nonmyeloablative HSCT compared to 52 underwent myeloablative HSCT (median ages, 56 and 54 years, respectively). The nonmyeloablative transplantation regimen consisted of low-dose TBI, proceeded in some patients by fludarabine administration and followed in all patients by immunosuppression with MMF and CSP. Those who underwent myeloablative HSCT were conditioned with different TBI- and non-TBI–containing regimens and received CSP plus methotrexate or MMF for GvHD prophylaxis. There were also no significant difference in the cumulative incidence of cGvHD requiring treatment (73% vs. 71%; p = 0.96).